January 9, 2017 8:33am


To evaluate the combination of CRS-207 with MRK’s KEYTRUDA® (pembrolizumab) for the treatment of Gastric Cancer



A clinical collaboration with Merck to investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of gastric cancer.

The multicenter P1 study is planned to begin in the first half of the year.


The Bottom Line: CRS-207 has demonstrated the ability to induce an anti-tumor immune response in clinical trials in other tumor types that over express the tumor antigen, mesothelin.  The combination of inducing an immune response through CRS-207, while simultaneously suppressing the cancer’s ability to evade the immune system through a PD-1 checkpoint inhibitor, has resulted in synergistic anti-tumor activity in pre-clinical studies. Key words - might and could … it’s a P1 and the question is further “tripped”  as enrolled patients with metastatic gastric cancer include those … who have failed at least two prior therapies to receive the combination of CRS-207 and pembrolizumab. 

ADRO closed DOWN -$0.20 to $11.90, news is news and a positive that won’t last but, is worth a pop – BUY and then bolt